

DR Market Announcement

J.P.Morgan

July 18, 2022

JPMorgan Chase Bank, N.A.
500 Stanton Christiana Rd.
Newark, DE 19713-2107
Phone: 800-990-1135
Fax: 302-220-4591

Attn: New York Stock Exchange

Security Name: GSK plc (GSK) - ADR - Spin Off / Share Consolidation – Updated Announcement
CUSIP: 37733W105

Updated Announcement following Announcement of June 24, 2022 to advise of GSK plc exchange rate with regard to share consolidation

Please be advised of the following Corporate Action information for the above noted Depositary Receipt (DR) program:

Corporate Action Type: Spin Off with DR Distribution
Spin Off DR Issuer Name: GSK plc
Spin Off DR CUSIP: 37733W105
Spin Off DR Ticker: GSK
Spin Off DR Ratio: 1 DR: 2 ORDS
DR Distribution Rate: 1 new Haleon plc DR issued for every 1 existing GSK plc DR held on DR Record Date
Tax Withholding Rate: N/A
Underlying Share Record Date: July 15, 2022
Underlying Share Payment Date: July 18, 2022
DR Record Date: July 15, 2022
DR Payment Date: July 21, 2022
DR Issuance and Cancellation Books closed Date: July 14, 2022
DR Issuance and Cancellation Books reopen Date: July 25, 2022
Fees: Issuance fee: \$0.00 per Haleon plc DR issued
New Security Name: Haleon plc
New Security CUSIP: 405552100
New Security Symbol: HLN
Haleon plc DR ratio: 1 DR : 2 ORDS

In connection with the above spin-off, GSK plc is proceeding with a share consolidation:

Corporate Action Type: Share Consolidation
GSK plc OLD CUSIP: 37733W105
GSK plc NEW CUSIP: 37733W204 – effective July 19, 2022
Underlying Share Record Date: July 18, 2022
Underlying Exchange Rate: 4 new ordinary shares for every 5 existing ordinary shares
Underlying Share Payment Date of New GSK plc Ordinary Shares: July 19, 2022
Underlying GSK plc Share New ISIN / Effective Date: GB00BN7SWP63 / July 19, 2022
DR Mandatory Exchange Rate: 4 new GSK plc ADSs for every 5 existing GSK plc ADSs
DR Effective Date: July 19, 2022 - 9:30 AM NY Time
Fees: Cancellation fee : \$0.02 per existing GSK ADS surrendered so as to receive new GSK ADSs

If the aggregate number of new GSK ADSs to which a holder is entitled results in a fractional ADS, such fractions will be sold, if possible, and the net proceeds, if any, will be distributed to such holder.

Kindly note the anticipated Trading Schedule for the GSK plc (“GSK”), new GSK plc post-spin and post-consolidation (“GSK WI”), and Haleon plc (“HLN WI”) ADSs:

DR Market Announcement

J.P.Morgan

July 14	GSK “Regular Way” market (“GSK”) begins trading with “Due-Bills”
July 18	Haleon When Issued (“HLN WI”) trading begins
July 18	Last day of trading GSK “Regular Way” with “Due – Bills” (“GSK”)
July 19	GSK plc (CUSIP 37733W105) is suspended
	GSK plc (New CUSIP 37733W204) begins “When Issued” trading (“GSK WI”) (without the distribution value, and New Consolidated (split-adjusted GSK))
July 21	Last day of trading new GSK WI
July 21	Last day of trading HLN WI
July 22	New GSK plc begins trading “Regular Way” (“GSK”)
July 22	Haleon begins trading “Regular Way” (“HLN”)

Investor Disclosures

JPMorgan Chase Bank, N.A. or an affiliate, in its capacity as depositary bank (the “Depositary”) collects fees from holders of depositary receipts. The Depositary may (i) reimburse the issuer for certain expenses incurred by the issuer in connection with the depositary receipts program and/or (ii) share with the issuer revenue derived by or anticipated to be derived by the Depositary from the program. The Depositary may use brokers, dealers or other service providers that are affiliates or other business units of JPMorgan Chase Bank, N.A. (the “Bank”) and, in doing so, each may earn or share fees and commissions.

In addition, to facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions and other corporate actions, the Depositary may engage the foreign exchange desk within the Bank and/or its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars (“FX Transactions”).

For further details relating to the applicable foreign exchange rate, any applicable spread and the execution of FX Transactions, see the “Disclosure” page (or successor page) of www.adr.com (as updated by the Depositary from time to time).

Execution Disclosure

J.P. Morgan acting as depositary for depositary receipt (“DR”) programs may facilitate the sale and purchase of securities in accordance with the applicable deposit agreement or the terms and condition of an unsponsored depositary receipts program. J.P. Morgan also acts as registrar and dividend disbursing agent for certain New York Registered Share (“NYRS”) programs of issuers incorporated in the Netherlands. The procedures set forth below apply to any sales/purchases required under sponsored or unsponsored DR programs or a NYRS appointment to the extent such sales/purchases are contemplated in the terms of such appointment. Sales or purchases may be executed in the jurisdiction of incorporation of a DR issuer or in the market where the DRs or NYRSs are listed and/or traded. Examples include but are not limited to:

- o a sale in the local market of rights to subscribe to underlying equity shares of an Issuer, where such rights are not registered in the US (or other jurisdiction if registration is required);
- o a sale of shares issued as a result of the acquisition of a DR issuer;
- o a sale of corporate action-related entitlements that are not distributed to DR holders;
- o the purchase of local shares with a foreign currency cash remittance that cannot be converted to US dollars; and
- o a sale of securities underlying DRs that remain outstanding subsequent to the termination of a DR

program. Any exceptions to these procedures will be made in accordance with J.P. Morgan’s policies.

Execution of sale or purchase of securities

If J.P. Morgan is required to endeavor to sell or purchase securities for the benefit of DR or NYRS holders, it may instruct the J.P. Morgan Equity Trading Desk (“JPM trading desk”) acting as principal or agent to execute the transaction. JPM trading desk may charge a commission of up to 5 basis points (unless otherwise disclosed) calculated on the execution price (subject to rounding). If the JPM trading desk does not have the capability to buy or sell securities in the relevant market or is unable to perform the trade for any reason, J.P. Morgan may instruct its appointed local market custodian or a local broker to execute the sale or purchase, as the case may be. Any such local market custodian or local broker may charge a commission in relation to the execution of any such sale or purchase transaction. Sales or purchases executed through agents other than a JPM trading desk or J.P. Morgan’s local market custodian will only be made in accordance with the policies of J.P. Morgan.

Execution Period

J.P. Morgan will endeavor to execute the full sale/purchase during the applicable trading period and in the applicable markets of the security to the best of its ability. Sales transactions will only commence subsequent to confirmation by J.P. Morgan of receipt of the security to be sold.

Absent a specific trading period, J.P. Morgan will instruct the JPM trading desk, the local custodian or the local broker, as the case may be to execute a sale or purchase as

DR Market Announcement

J.P.Morgan

soon as reasonably practicable as market conditions will permit, endeavoring to complete such sale or purchase within five (5) business days. The execution price for the securities bought or sold will depend on market conditions, including but not limited to:

- a. volume of securities subject to the trade;
- b. influence of the trade on market value of securities;
- c. historic trading volumes of the securities; and
- d. number of counterparties interested in the trade.

J.P. Morgan does not guarantee that the securities will be purchased or sold or at any particular price.

Final Price

J.P. Morgan will base the final price ("Final Price") on the actual execution price for the sale or purchase as adjusted for costs and commissions as described below.

The Final Price for executions of trades over a trading period of more than one day will be determined based on the weighted average of the final prices of all the sales/purchases of securities carried out on behalf of J.P. Morgan and on its instructions that occurred over each day of the trading period taking into account the highest and lowest price traded on all days of the trading period during normal trading hours of the exchange or market where the security trades. Any conversion of foreign currency into US dollars that may be required will be undertaken in accordance with the foreign exchange policies of J.P. Morgan in place at that time. Please consult the additional disclosure for more information: [Depository Receipts FX Disclosure]

The Final Price will be determined net of certain incurred costs or commissions, including but not limited to: (i) commission paid to a JPM trading desk, local custodian, local broker or other agent; (ii) stock exchange fees; (iii) applicable taxes and governmental charges; and (iv) any sale coordination fee of J.P. Morgan of up to 20 basis points calculated on the execution price (subject to rounding), with such fee to be assessed only in accordance with the terms and conditions of the applicable program and to the extent it would not cause the Final Price to fall outside of the range of prices for the security on that day during normal trading hours of the exchange or market where the security trades.

Disclaimer: Each of the Depository, the Bank and/or its affiliates reserves the right to change any of the above execution policies at any time in its discretion. This document is provided solely for informational purposes and provides a summary of the information contained herein. It is not a complete description of the transactions, processes and procedures referred to herein. Processes and procedures described in, and any other content of, this document are subject to change without notice. Neither the Depository, the Bank nor any of their affiliates accept any obligation to update this document, whether or not such processes and/or procedures have changed.

© 2022 JPMorgan Chase & Co. All rights reserved.